These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 11111965)

  • 1. Randomised open clinical trial of conversion from mycophenolate mofetil to azathioprine in cadaveric renal transplantation.
    Nowacka-Cieciura E; Kamiñska B; Cieciura T; Gradowska L; Pazik J; Lao M; Rowiñski W; Paczek L
    Transpl Int; 2000; 13 Suppl 1():S68-72. PubMed ID: 11111965
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mycophenolate mofetil for the treatment of a first acute renal allograft rejection: three-year follow-up. The Mycophenolate Mofetil Acute Renal Rejection Study Group.
    Mycophenolate Mofetil Acute Renal Rejection Study Group
    Transplantation; 2001 Apr; 71(8):1091-7. PubMed ID: 11374408
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group.
    Transplantation; 1996 Apr; 61(7):1029-37. PubMed ID: 8623181
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group.
    Sollinger HW
    Transplantation; 1995 Aug; 60(3):225-32. PubMed ID: 7645033
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Conversion from mycophenolate mofetil to azathioprine in high-risk renal allograft recipients on cyclosporine-based immunosuppression.
    Lou HX; Vathsala A
    Transplant Proc; 2004 Sep; 36(7):2090-1. PubMed ID: 15518756
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized trial of tacrolimus plus mycophenolate mofetil or azathioprine versus cyclosporine oral solution (modified) plus mycophenolate mofetil after cadaveric kidney transplantation: results at 2 years.
    Ahsan N; Johnson C; Gonwa T; Halloran P; Stegall M; Hardy M; Metzger R; Shield C; Rocher L; Scandling J; Sorensen J; Mulloy L; Light J; Corwin C; Danovitch G; Wachs M; VanVeldhuisen P; Salm K; Tolzman D; Fitzsimmons WE
    Transplantation; 2001 Jul; 72(2):245-50. PubMed ID: 11477347
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized trial with steroids and antithymocyte globulins comparing cyclosporine/azathioprine versus tacrolimus/mycophenolate mofetil (CATM2) in renal transplantation.
    Vacher-Coponat H; Moal V; Indreies M; Purgus R; Loundou A; Burtey S; Brunet P; Moussi-Frances J; Daniel L; Dussol B; Berland Y
    Transplantation; 2012 Feb; 93(4):437-43. PubMed ID: 22228415
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized trial of tacrolimus + mycophenolate mofetil or azathioprine versus cyclosporine + mycophenolate mofetil after cadaveric kidney transplantation: results at three years.
    Gonwa T; Johnson C; Ahsan N; Alfrey EJ; Halloran P; Stegall M; Hardy M; Metzger R; Shield C; Rocher L; Scandling J; Sorensen J; Mulloy L; Light J; Corwin C; Danovitch G; Wachs M; VanVeldhuisen P; Leonhardt M; Fitzsimmons WE
    Transplantation; 2003 Jun; 75(12):2048-53. PubMed ID: 12829910
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Necessity and safety of conversion from mycophenolate mofetil to AzA thioprine after renal transplantation].
    Lu JS; Xiao XR; Ao JH; Gao JP; Dong J; Hong BF; Li YT
    Zhonghua Yi Xue Za Zhi; 2005 Mar; 85(10):657-60. PubMed ID: 15932725
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Conversion from mycophenolate mofetil to azathioprine in renal allograft [corrected] patients within the first month posttransplantation.
    Zhu B; Liu Z; Wu C; Wang P; Wang X; Xu H
    Transplant Proc; 2008 Sep; 40(7):2258-61. PubMed ID: 18790207
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mycophenolic acid versus azathioprine as primary immunosuppression for kidney transplant recipients.
    Wagner M; Earley AK; Webster AC; Schmid CH; Balk EM; Uhlig K
    Cochrane Database Syst Rev; 2015 Dec; 2015(12):CD007746. PubMed ID: 26633102
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safe conversion of mycophenolate mofetil to azathioprine in kidney transplant recipients with sirolimus-based immunosuppression.
    El-Agroudy AE; El-Dahshan KF; Wafa EW; Sheashaa HA; Gad ZA; Ismail AM; Shokeir AA; Ghoneim MA
    Nephrology (Carlton); 2009 Apr; 14(2):255-61. PubMed ID: 19017277
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized trial of tacrolimus (Prograf) in combination with azathioprine or mycophenolate mofetil versus cyclosporine (Neoral) with mycophenolate mofetil after cadaveric kidney transplantation.
    Johnson C; Ahsan N; Gonwa T; Halloran P; Stegall M; Hardy M; Metzger R; Shield C; Rocher L; Scandling J; Sorensen J; Mulloy L; Light J; Corwin C; Danovitch G; Wachs M; van Veldhuisen P; Salm K; Tolzman D; Fitzsimmons WE
    Transplantation; 2000 Mar; 69(5):834-41. PubMed ID: 10755536
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mycophenolate mofetil for the treatment of a first acute renal allograft rejection: The Mycophenolate Mofetil Acute Renal Rejection Study Group.
    Transplantation; 1998 Jan; 65(2):235-41. PubMed ID: 9458021
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison between mycophenolate mofetil- and azathioprine-based immunosuppressions in clinical lung transplantation.
    Zuckermann A; Klepetko W; Birsan T; Taghavi S; Artemiou O; Wisser W; Dekan G; Wolner E
    J Heart Lung Transplant; 1999 May; 18(5):432-40. PubMed ID: 10363687
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcome in cadaveric renal transplant recipients treated with cyclosporine A and mycophenolate mofetil versus cyclosporine A and azathioprine.
    Lee CM; Markezich AJ; Scandling JD; Dafoe DC; Alfrey EJ
    J Surg Res; 1998 May; 76(2):131-6. PubMed ID: 9698512
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized, prospective trial of mycophenolate mofetil versus azathioprine for prevention of acute renal allograft rejection after simultaneous kidney-pancreas transplantation.
    Merion RM; Henry ML; Melzer JS; Sollinger HW; Sutherland DE; Taylor RJ
    Transplantation; 2000 Jul; 70(1):105-11. PubMed ID: 10919583
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduced human IgG anti-ATGAM antibody formation in renal transplant recipients receiving mycophenolate mofetil.
    Kimball JA; Pescovitz MD; Book BK; Norman DJ
    Transplantation; 1995 Dec; 60(12):1379-83. PubMed ID: 8545860
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of mycophenolate mofetil versus azathioprine as adjunctive therapy to cyclosporine on the rates of renal allograft loss due to glomerular disease recurrence.
    Pham PT; Pham PC
    Nephrol Dial Transplant; 2012 Jul; 27(7):2965-71. PubMed ID: 22207327
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduced kidney transplant rejection rate and pharmacoeconomic advantage of mycophenolate mofetil.
    Wüthrich RP; Weinreich T; Ambühl PM; Schwarzkopf AK; Candinas D; Binswanger U
    Nephrol Dial Transplant; 1999 Feb; 14(2):394-9. PubMed ID: 10069195
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.